Table 4.
Clinical trials targeting IL-10 for cancer therapy
| Products | NCT number | Cancer types | Combination partners | Phases | Status |
|---|---|---|---|---|---|
| Pegilodecakin (PEGylated IL-10) | NCT02923921 | Pancreatic Cancer | FOLFOX | III | Completed |
| NCT03382912 | NSCLC | Nivolumab | II | Terminated | |
| NCT03382899 | NSCLC | Pembrolizumab | II | Terminated | |
| NCT02009449 | Solid tumors | Chemotherapy | I | Active, not recruiting | |
| IBB0979 (B7H3-IL10 immunocytokine) | NCT05991583 | Solid tumors | Monotherapy | I/II | Recruiting |
| IAE0972 (EGFR/IL10 immunocytokine) | NCT05396339 | Solid tumors | Monotherapy | I/II | Recruiting |
Note: NSCLC non-small cell lung cancer, FOLFOX 5-fluorouracil and oxaliplatin, EGFR epidermal growth factor receptor